RBC Capital Reiterates Sector Perform on Biomarin Pharmaceutical, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has reiterated its Sector Perform rating on Biomarin Pharmaceutical and maintained a price target of $80.
October 30, 2024 | 3:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital has reiterated its Sector Perform rating on Biomarin Pharmaceutical and maintained a price target of $80.
The reiteration of a Sector Perform rating and maintenance of the $80 price target by RBC Capital suggests a neutral outlook for Biomarin Pharmaceutical. This indicates that the stock is expected to perform in line with the sector, and there are no significant changes in the analyst's view. The impact on the stock price is likely neutral in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100